Use of alemtuzumab and rituximab consolidation in CLL: Pros and cons
Thomas Elter, Barbara F. Eichhorst, Clemens-Martin WendtnerVolume:
4
Language:
english
Pages:
4
DOI:
10.1007/s11899-009-0006-5
Date:
January, 2009
File:
PDF, 242 KB
english, 2009